We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Silexion Therapeutics Corporation | NASDAQ:SLXN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09 | -9.57% | 0.85 | 0.85 | 0.881 | 0.94 | 0.84 | 0.9393 | 968,394 | 00:59:11 |
From Nov 2024 to Jan 2025
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company’s management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida.
Ilan Hadar, Chief Executive Officer will deliver a company presentation titled “Transforming Cancer Care: Silexion Therapeutics’ Innovative Approach to Pancreatic Cancer” on December 4, 2024 at 11:30 am. A replay of the presentation will be posted, when available, to Silexion’s website on the Presentation & Events page of the investors section.
The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact the Noble investor outreach team to schedule a meeting.
About Silexion Therapuetics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Company ContactSilexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@silexion.com
Investor ContactARX | Capital Markets AdvisorsNorth American Equities Desksilexion@arxadvisory.com
1 Year Silexion Therapeutics Chart |
1 Month Silexion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
